Psychedelics R&D

MindMed’s (NASDAQ: MNMD) heated proxy battle over R&D strategy might finally be coming to an end. On Wednesday, June 21, the company announced a preliminary vote assessment that showed shareholders elected all six of its nominees at the annual meeting. As stated by the...

After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30, 2022: Total cash was $324,146 Net loss due to common stockholders was $8.09 million from...

In a new assessment report, the market research & consulting firm InsightAce Analytic stated that the global psychedelic therapeutics market was valued at US$ 3.61 billion in 2021 and is expected to reach US$ 8.31 billion by 2028, with a compound annual growth rate (CAGR) of...

Private psychedelics biotech company Gilgamesh Pharmaceuticals is currently developing a diverse portfolio of novel, potentially first-in-class compounds targeting mechanisms with demonstrated clinical efficacy, onset duration or prolonged treatment duration, for the treatment of psychiatric...